UBS analyst Kevin Caliendo raised the firm’s price target on Cardinal Health to $125 from $122 and keeps a Buy rating on the shares. Mix and timing played a “meaningful” part in Cardinal’s disappointing Pharma results, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CAH:
- Cardinal Health price target raised to $109 from $96 at TD Cowen
- Cardinal Health price target raised to $133 from $128 at Baird
- Cardinal Health Executives to Discuss Quarterly Results and Outlook
- Cardinal Health price target raised to $115 from $112 at BofA
- Cardinal Health raises FY24 EPS view to $7.20 to $7.35 from $6.75-$7.00
